Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

OV350 SHOWED A GOOD SAFETY PROFILE, SUPPORTING THE ADVANCEMENT OF THE COMPANY'S KCC2 PORTFOLIO, INCLUDING THE FIRST ORAL DIRECT ACTIVATOR, OV4071 THERE WERE NO TREATMENT-RELATED LABORATORY FINDINGS, NO SAFETY FINDINGS, AND NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS (SAES) EXPLORATORY QUANTITATIVE ELECTROPHYSIOLOGY RESULTS SUGGEST OV350 HAD CENTRAL ACTIVITY AND SPECTRAL POWER CONSISTENT WITH EXPECTED PHYSIOLOGICAL EFFECTS OF KCC2 MODULATION; ALIGNED WITH EXPECTED DRUG EXPOSURE IN THE BRAIN PHARMACOKINETICS FOR OV350 WERE AS PREDICTED, AND WILL INFORM DOSING STRATEGIES FOR FUTURE KCC2 DEVELOPMENT PROGRAMS OV4071 (ORAL) IS ON TRACK FOR REGULATORY SUBMISSION FOR A PHASE 1/1B CLINICAL TRIAL IN Q1 2026 NEW YORK, DEC. 18, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES TO TREAT BRAIN DISORDERS AND SYMPTOMS CAUSED BY EXCESS NEURAL EXCITABILITY, TODAY ANNOUNCED RESULTS FROM ITS PHASE 1 STUDY OF OV350, THE FIRST-EVER KCC2 DIRECT ACTIVATOR KNOWN TO BE DOSED IN HUMANS. THE STUDY MET ITS PRIMARY OBJECTIVES TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS.

OVID THERAPEUTICS REPORTS PHASE 1 RESULTS FOR THE FIRST-EVER DIRECT ACTIVATOR OF POTASSIUM-CHLORIDE COTRANSPORTER 2 (KCC2), OV350 INTRAVENOUS (IV)

NEW YORK, DEC. 02, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THE APPOINTMENT OF PETRA KAUFMANN, M.D., M.S., F.A.A.N., AS CHIEF MEDICAL OFFICER. DR. KAUFMANN JOINS OVID'S LEADERSHIP TEAM WITH RESPONSIBILITY FOR GUIDING CLINICAL, MEDICAL, AND REGULATORY STRATEGY AS THE COMPANY PROGRESSES A CLINICAL PIPELINE OF POTENTIAL BEST- AND FIRST-IN-CLASS THERAPEUTIC CANDIDATES FOR CONDITIONS AND SYMPTOMS DRIVEN BY NEURONAL IMBALANCE.

OVID THERAPEUTICS APPOINTS DR. PETRA KAUFMANN AS CHIEF MEDICAL OFFICER

MEG ALEXANDER APPOINTED CHIEF EXECUTIVE OFFICER EFFECTIVE JANUARY 1, 2026; DR. JEREMY M. LEVIN TO TRANSITION TO EXECUTIVE CHAIR OF THE BOARD OF DIRECTORS NEXT-GENERATION GABA-AMINOTRANSFERASE (GABA-AT) INHIBITOR, OV329, DEMONSTRATED STRONG INHIBITORY ACTIVITY AND A POTENTIAL BEST-IN-CATEGORY SAFETY PROFILE IN A PHASE 1 STUDY, SUPPORTING ADVANCEMENT INTO PLANNED PHASE 2 PATIENT STUDIES OV329 PHASE 1 RESULTS SELECTED FOR LATE-BREAKING POSTER PRESENTATION AT THE 2025 AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING OVID'S FIRST-IN-CLASS KCC2 DIRECT ACTIVATOR PORTFOLIO IS PROGRESSING ON-TRACK WITH FIRST-IN-HUMAN DATA FOR OV350 INTRAVENOUS (IV) EXPECTED IN Q4 2025 AND THE FIRST-EVER ORAL KCC2 DIRECT ACTIVATOR, OV4071, ANTICIPATED TO ENTER THE CLINIC IN Q2 2026 COMPLETED PRIVATE PLACEMENT OF UP TO $175 MILLION IN GROSS PROCEEDS, INCLUDING INITIAL CLOSING OF APPROXIMATELY $81 MILLION, EXPECTED TO EXTEND ANTICIPATED CASH RUNWAY INTO 2H 2028 NEW YORK, NOV. 12, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED A CHIEF EXECUTIVE OFFICER (CEO) SUCCESSION PLAN UNDER WHICH MEG ALEXANDER WILL ASSUME THE ROLE OF CEO AND JOIN OVID'S BOARD OF DIRECTORS, EFFECTIVE JANUARY 1, 2026.

OVID THERAPEUTICS ANNOUNCES PLANNED LEADERSHIP SUCCESSION AND REPORTS BUSINESS UPDATES AND THIRD QUARTER 2025 FINANCIAL RESULTS

INITIAL CLOSING OF APPROXIMATELY $81 MILLION EXPECTED TO FUND CURRENT OPERATING PLAN AND CLINICAL PIPELINE INTO 2028, WITH POTENTIAL FOR UP TO $94 MILLION IN ADDITIONAL PROCEEDS UPON EXERCISE OF ISSUED WARRANTS INITIAL CLOSING OF APPROXIMATELY $81 MILLION EXPECTED TO FUND CURRENT OPERATING PLAN AND CLINICAL PIPELINE INTO 2028, WITH POTENTIAL FOR UP TO $94 MILLION IN ADDITIONAL PROCEEDS UPON EXERCISE OF ISSUED WARRANTS

OVID THERAPEUTICS ANNOUNCES PRICING OF PRIVATE PLACEMENT TOTALING UP TO $175 MILLION IN GROSS PROCEEDS

NEW YORK, OCT. 03, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN CONDITIONS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PHASE 1 HEALTHY VOLUNTEER STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) ACTIVITY OF OV329, A NEXT GENERATION GABA-AMINOTRANSFERASE (GABA-AT) INHIBITOR BEING DEVELOPED FOR DRUG-RESISTANT EPILEPSIES.

OVID ANNOUNCES POSITIVE TOPLINE RESULTS FOR THE NEXT-GENERATION GABA-AMINOTRANSFERASE INHIBITOR, OV329, THAT DEMONSTRATE STRONG INHIBITORY ACTIVITY AND A POTENTIAL BEST-IN-CATEGORY SAFETY PROFILE

TOPLINE RESULTS FROM THE OV329 PHASE 1 SAFETY, TOLERABILITY AND BIOMARKER STUDY REMAIN ON TRACK FOR A READOUT IN Q3 2025 $7.0 MILLION ROYALTY MONETIZATION AGREEMENT SIGNED WITH IMMEDICA PHARMA AB FOR FUTURE GANAXOLONE ROYALTIES, DELIVERING CAPITAL TO THE COMPANY FROM A NON-PIPELINE ASSET OV4071, THE FIRST EVER ORAL KCC2 DIRECT ACTIVATOR, IS COMPLETING AN IND-ENABLING PACKAGE; OVID ANTICIPATES FIRST-IN-HUMAN STUDIES IN Q2 2026 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $38.3 MILLION AS OF JUNE30, 2025 ARE EXPECTED TO SUPPORT CURRENTLY PLANNED OPERATIONS AND DEVELOPMENT PROGRAMS INTO EARLY 2H 2026 NEW YORK, AUG. 13, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN CONDITIONS WITH SIGNIFICANT UNMET NEED, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE30, 2025. OUR PIPELINE CONTINUES TO ADVANCE ACROSS MULTIPLE FRONTS, WITH SEVERAL KEY READOUTS ANTICIPATED IN THE NEAR AND MID-TERM.

OVID THERAPEUTICS REPORTS BUSINESS UPDATES AND SECOND QUARTER 2025 FINANCIAL RESULTS

NEW YORK, JULY 23, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN CONDITIONS WITH SIGNIFICANT UNMET NEED, ANNOUNCED TODAY THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE IN THE BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE BEING HELD ONJULY 29-30, 2025. ABOUT OVID THERAPEUTICS OVID THERAPEUTICS INC. IS A NEW YORK-BASED BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN CONDITIONS WITH SIGNIFICANT UNMET NEED.

OVID THERAPEUTICS TO PARTICIPATE IN THE BTIG VIRTUAL BIOTECH CONFERENCE

NON-DILUTIVE FUNDING EXTENDS OVID'S OPERATIONAL RUNWAY; IMMEDICA ASSUMES CERTAIN GANAXOLONE IP COSTS NON-DILUTIVE FUNDING EXTENDS OVID'S OPERATIONAL RUNWAY; IMMEDICA ASSUMES CERTAIN GANAXOLONE IP COSTS

OVID THERAPEUTICS ENTERS AGREEMENT WITH IMMEDICA PHARMA AB FOR SALE OF FUTURE GANAXOLONE ROYALTIES

TOPLINE PHARMACODYNAMIC BIOMARKER, SAFETY AND TOLERABILITY RESULTS FROM A PHASE 1 STUDY OF OV329 ARE ON TRACK TO READOUT IN Q3 2025 OVID'S FIRST PROGRAM IN ITS KCC2 DIRECT ACTIVATOR LIBRARY, OV350, HAS BEEN DOSED IN A PHASE 1 STUDY IN Q1 2025; SAFETY AND TOLERABILITY RESULTS EXPECTED BEFORE YEAR-END CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $43.0 MILLION AS OF MARCH31, 2025 ARE EXPECTED TO SUPPORT CURRENTLY PLANNED OPERATIONS AND DEVELOPMENT PROGRAMS INTO THE 2H OF 2026 NEW YORK, MAY 13, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN CONDITIONS WITH SIGNIFICANT UNMET NEED, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH31, 2025. WE'RE OFF TO A STRONG START ACROSS OUR PIPELINE AND PROGRAMS IN WHAT WILL BE A DEFINING YEAR FOR OVID, SAID DR. JEREMY LEVIN, D.PHIL.

OVID THERAPEUTICS REPORTS BUSINESS UPDATES AND FIRST QUARTER 2025 FINANCIAL RESULTS

STELIOS PAPADOPOLOUS, PH.D., A PIONEERING LEADER IN BIOTECH, APPOINTED TO BOARD OF DIRECTORS; TWO INDUSTRY VETERANS JOINED MANAGEMENT TEAM AS OVID PREPARES TO TAKE OV329 INTO PATIENT TRIALS AND MOVE ITS FIRST KCC2 DIRECT ACTIVATOR INTO THE CLINIC TOPLINE RESULTS FROM PHASE 1 STUDY OF OV329 EXPECTED IN Q3 2025, WHICH WILL INCLUDE BIOMARKERS THAT MEASURE CLINICAL EFFECT AND TARGET ENGAGEMENT, SAFETY, AND TOLERABILITY OV350, OVID'S FIRST PROGRAM IN ITS KCC2 DIRECT ACTIVATOR LIBRARY, INITIATED A FIRST-IN-HUMAN STUDY IN Q1 2025 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $53.1MILLION AS OF DECEMBER31, 2024, ARE EXPECTED TO SUPPORT OPERATIONS AND DEVELOPMENT PROGRAMS INTO THE SECOND HALF OF 2026 NEW YORK, MARCH 11, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN CONDITIONS WITH SIGNIFICANT UNMET NEED, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER31, 2024.

OVID THERAPEUTICS REPORTS BUSINESS UPDATES AND FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

NEW YORK, MARCH 03, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING SMALL-MOLECULE MEDICINES FOR BRAIN CONDITIONS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THE APPOINTMENT OF STELIOS PAPADOPOULOS, PH.D. TO ITS BOARD OF DIRECTORS.

Ovid Therapeutics Inc.

OVID

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ovid Therapeutics Inc.

OVID.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OVID